ONE Bio Corp. (ONBI)
| Market Cap | 4.19K |
| Revenue (ttm) | 53.91M |
| Net Income (ttm) | 8.94M |
| Shares Out | 8.37M |
| EPS (ttm) | 1.22 |
| PE Ratio | 0.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 25,000 |
| Average Volume | 7,300 |
| Open | 0.0005 |
| Previous Close | 0.0005 |
| Day's Range | 0.0005 - 0.0005 |
| 52-Week Range | 0.0002 - 0.0200 |
| Beta | 4.28 |
| RSI | n/a |
| Earnings Date | n/a |
About ONE Bio
ONE Bio Corp., an agritech company, together with its subsidiaries, utilizes green process manufacturing to produce raw chemicals and herbal extracts, natural supplements, and organic products. The company operates through two business units, Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE business unit engages in the development, manufacture, and commercialization of bio-ecological products and over-the-counter products utilizing the extractions of tobacco leaves and various other plant materials. It produces chemical and... [Read more]
Financial Performance
In 2010, ONE Bio's revenue was $52.30 million, an increase of 136.92% compared to the previous year's $22.07 million. Earnings were $8.68 million, an increase of 81.79%.
Financial StatementsNews
Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal
Jiangsu Hengrui Pharma out-licensed global rights for an anti-inflammatory drug to ONE Bio in a $1 billion deal. Shanghai Sangon Biotech raised $290 million in funding from private investors. Hangzhou...